• Lilly Reports LARTRUVO Study Did Not Meet Primary Endpoint americanpharmaceuticalreview
    January 23, 2019
    Eli Lilly and Company reported the results of ANNOUNCE, the Phase 3 study of LARTRUVO (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS)....
PharmaSources Customer Service